2025
Artificial Intelligence Algorithm Predicts Response to Immune Checkpoint Inhibitors.
Fa'ak F, Coudray N, Jour G, Ibrahim M, Illa-Bochaca I, Qiu S, Claudio Quiros A, Yuan K, Johnson D, Rimm D, Weber J, Tsirigos A, Osman I. Artificial Intelligence Algorithm Predicts Response to Immune Checkpoint Inhibitors. Clinical Cancer Research 2025 PMID: 40553453, DOI: 10.1158/1078-0432.ccr-24-3720.Peer-Reviewed Original ResearchResponse to ICIImmune checkpoint inhibitorsMetastatic melanoma cohortCheckpoint inhibitorsMelanoma cohortMelanoma treated with immune checkpoint inhibitorsBiomarkers of ICI responseImmune checkpoint inhibitor useImmune checkpoint inhibitor treatmentCohort of melanoma patientsLow tumor stroma ratioProgression-free survivalTumor-stroma ratioSignificant adverse eventsArea under the curvePatient overall survivalMetastatic settingUnresectable melanomaEpithelioid histologyICI responseMelanoma patientsMetastatic melanomaOverall survivalPatient survivalTumor featuresSurvival of patients diagnosed with stage IV cancer in 2020 based on COVID-19 status.
Ayoade O, Canavan M, Caturegli G, Zolfaghari E, Resio B, Woodard G, Boffa D. Survival of patients diagnosed with stage IV cancer in 2020 based on COVID-19 status. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e24041.Peer-Reviewed Original ResearchCancer patient survivalPatient survivalTumor behaviorCOVID-19 infectionCancer typesCharlson-Deyo scoreNational Cancer DatabaseSurvival of patientsKaplan Meier analysisCox proportional hazards modelsStage IV cancerAssociated with lower mortality riskProportional hazards modelCOVID-positive patientsMeier analysisCancer DatabaseLower mortality riskPositive patientsTreatment modalitiesDeyo scoreIV cancerImmune modulationImmunological consequencesCancer patientsYear mortalityClinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT
Gurnari C, Robin M, Adès L, Aljurf M, Almeida A, Duarte F, Bernard E, Cutler C, Della Porta M, De Witte T, DeZern A, Drozd-Sokolowska J, Duncavage E, Fenaux P, Gagelmann N, Garcia-Manero G, Haferlach C, Haferlach T, Hasserjian R, Hellström-Lindberg E, Jacoby M, Kulasekararaj A, Lindsley R, Maciejewski J, Makishima H, Malcovati L, Mittelman M, Myhre A, Ogawa S, Onida F, Papaemmanuil E, Passweg J, Platzbecker U, Pleyer L, Raj K, Santini V, Sureda A, Tobiasson M, Voso M, Yakoub-Agha I, Zeidan A, Walter M, Kröger N, McLornan D, Cazzola M. Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT. Blood 2025, 145: 1987-2001. PMID: 39970324, DOI: 10.1182/blood.2024025131.Peer-Reviewed Original ResearchAllo-HCTMolecular International Prognostic Scoring SystemGenomic profilingInternational Prognostic Scoring SystemAllogeneic hematopoietic cell transplantationAssociated with superior clinical outcomesMutant hematopoietic cellsNon-transplant therapiesPrognostic scoring systemHematopoietic cell transplantationClinical practiceTime of diagnosisSuperior clinical outcomesEstimate patient survivalIPSS-MAllo-HSCTCell transplantationExpert international panelPatient survivalPredisposition variantsTherapeutic optionsClinical outcomesCurative treatmentGenetic abnormalitiesHematopoietic cellsOverall Survival Prediction of Brain Tumor Patients with Multimodal MRI using Swin Unetr
Kim G, Xing F, Kong H, Santarnecchi E, Shih H, Bortfeld T, Fakhri G, Liu X, Choi J, Woo J. Overall Survival Prediction of Brain Tumor Patients with Multimodal MRI using Swin Unetr. 2025, 00: 1-5. DOI: 10.1109/isbi60581.2025.10981128.Peer-Reviewed Original ResearchMultimodal magnetic resonance imagingBrain tumor patientsGlioblastoma patient survivalPersonalized treatment plansSurvival prediction performanceMultimodal MRIOverall survival predictionMagnetic resonance imagingHand-crafted featuresState-of-the-artMulti-scale featuresMulti-task frameworkPatient survivalClinical prognosisTumor patientsGlioblastoma patientsSuperior segmentation accuracyTreatment planningResonance imagingSurvival prediction taskPredictive performanceSurvival predictionPrediction taskBRATS datasetSurvival5 Aurora kinase inhibition synergizes with Fanconi anemia pathway defects to limit tumorigenesis
Doorodian P, Nagarajan A, Burtness B, Kupfer G, Stahl E. 5 Aurora kinase inhibition synergizes with Fanconi anemia pathway defects to limit tumorigenesis. Journal Of Clinical And Translational Science 2025, 9: 1-2. PMCID: PMC12050673, DOI: 10.1017/cts.2024.697.Peer-Reviewed Original ResearchFA-D2MRNA expressionAurora kinasesPatient survivalHPV-negative head and neck cancersFanconi anemiaHomologous recombination deficiency scoresSynthetic lethal genesHead and neck cancerAssociated with poor patient survivalTumor mRNA expressionPan-cancer datasetKnockdown of AURKADNA damage repairPoor patient survivalAurora kinase inhibitionTCGA pan-cancer datasetsIncreased ~5-foldMutant cellsAurora kinase inhibitorsFA mutationsCancer Genome AtlasTumor gradeDNA repair proficiencySiRNA-basedPredicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning
Bai Z, Osman M, Brendel M, Tangen C, Flaig T, Thompson I, Plets M, Scott Lucia M, Theodorescu D, Gustafson D, Daneshmand S, Meeks J, Choi W, Dinney C, Elemento O, Lerner S, McConkey D, Faltas B, Wang F. Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning. Npj Digital Medicine 2025, 8: 174. PMID: 40121304, PMCID: PMC11929913, DOI: 10.1038/s41746-025-01560-y.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerResponse to neoadjuvant chemotherapyNeoadjuvant chemotherapyBladder cancerPredicting response to neoadjuvant chemotherapyOptimal treatment strategyImprove patient survivalImproving clinical outcomesGene expression profilesBladder preservationPredictive biomarkersPatient survivalUnnecessary treatmentClinical outcomesTreatment responseRNA sequencingTumor heterogeneityTreatment strategiesClinical trialsGene signatureExpression profilesMolecular determinantsCancerChemotherapyBuilding accurate predictive models
2024
Charting the metabolic biogeography of the colorectum in cancer: challenging the right sided versus left sided classification
Jain A, Morris M, Berardi D, Arora T, Domingo-Almenara X, Paty P, Rattray N, Kerekes D, Lu L, Khan S, Johnson C. Charting the metabolic biogeography of the colorectum in cancer: challenging the right sided versus left sided classification. Molecular Cancer 2024, 23: 211. PMID: 39342363, PMCID: PMC11438248, DOI: 10.1186/s12943-024-02133-5.Peer-Reviewed Original ResearchConceptsRectal cancerNormal mucosaMetabolite abundancePatient-matched tumorTumor-specific metabolitesMetabolic heterogeneityPatient survivalRectosigmoid colonSigmoid colonAnatomic subsitePatient-matched normal mucosaTransverse colonMetabolomic profilesAscending colonCRC biomarkersMetabolome DatabaseDescending colonMetabolite changesLeft-sidedRight-sidedColorectumRisk factorsMetabolome mapCancerTumorNuclear PKM2 binds pre-mRNA at folded G-quadruplexes and reveals their gene regulatory role
Anastasakis D, Apostolidi M, Garman K, Polash A, Umar M, Meng Q, Scutenaire J, Jarvis J, Wang X, Haase A, Brownell I, Rinehart J, Hafner M. Nuclear PKM2 binds pre-mRNA at folded G-quadruplexes and reveals their gene regulatory role. Molecular Cell 2024, 84: 3775-3789.e6. PMID: 39153475, PMCID: PMC11455610, DOI: 10.1016/j.molcel.2024.07.025.Peer-Reviewed Original ResearchRNA-binding proteinsPre-mRNANon-canonical RNA-binding proteinsGene regulatory roleCancer cellsRNA G-quadruplexesG-quadruplexInvasion of cancer cellsTriple-negative breast cancer cellsBreast cancer cellsEpithelial-to-mesenchymal transitionCancer typesNuclear localizationPrecursor mRNANuclear accumulationGene expressionXenograft mouse modelNuclear PKM2Regulatory roleRG4sPKM2Reduced migrationMouse modelTumor progressionPatient survivalOutcomes of repeat conventional transarterial chemoembolization in patients with liver metastases
Ghabili K, Windham-Herman A, Konstantinidis M, Murali N, Borde T, Adam L, Laage-Gaupp F, Lin M, Chapiro J, Georgiades C, Nezami N. Outcomes of repeat conventional transarterial chemoembolization in patients with liver metastases. Annals Of Hepatology 2024, 29: 101529. PMID: 39033928, PMCID: PMC11558520, DOI: 10.1016/j.aohep.2024.101529.Peer-Reviewed Original ResearchConventional transarterial chemoembolizationLiver metastasesNeuroendocrine tumorsColorectal carcinomaTransarterial chemoembolizationOverall survivalLung cancerAssociated with improved patient survivalManagement of liver metastasesMetastatic liver lesionsSingle-institution analysisNonresponding patientsSurvival outcomesPatient survivalResponse assessmentTarget lesionsMetastasisLiver lesionsPatientsResponse rateChemoembolizationSurvivalLiverLesionsCancerWaiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study
Vitale A, Trapani S, Russo F, Miele L, Baroni G, Marchesini G, Burra P, Ottoveggio M, Romagnoli R, Martini S, De Simone P, Carrai P, Cescon M, Morelli M, De Carlis L, Belli L, Gruttadauria S, Volpes R, Colledan M, Fagiuoli S, Di Benedetto F, De Maria N, Rossi G, Caccamo L, Donato F, Vennarecci G, Di Costanzo G, Vivarelli M, Carraro A, Sacerdoti D, Ettorre G, Giannelli V, Agnes S, Gasbarrini A, Rossi M, Corradini S, Mazzaferro V, Bhoori S, Manzia T, Lenci I, Zamboni F, Mameli L, Baccarani U, Toniutto P, Lupo L, Tandoi F, Rendina M, Andorno E, Giannini E, Spada M, Billato I, Marchini A, Romano P, Brancaccio G, D’Amico F, Ricci A, Cardillo M, Cillo U, del Fegato . A, . S, Trapianti C. Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study. JHEP Reports 2024, 6: 101147. PMID: 39282226, PMCID: PMC11399673, DOI: 10.1016/j.jhepr.2024.101147.Peer-Reviewed Original ResearchSurvival benefit of patientsTransplant survival benefitHepatocellular carcinomaLiver transplantationLiver diseaseIncreased waitlist mortalityPatient survivalBenefit of patientsSteatotic liver diseaseEnd-stage chronic liver diseaseAbstractText Label="Background &Waiting listImprove patient survivalWaitlist mortalityLiver transplant indicationsChronic liver diseaseAlcoholic liver diseaseRisk of deathWaiting list mortalityAbstractText Label="ImpactPrognostic featuresTransplant eligibility criteriaSurvival benefitTransplant indicationAdult patientsTemporary Mechanical Circulatory Support after Cardiac Surgery
Keller S, Whitman G, Grant M. Temporary Mechanical Circulatory Support after Cardiac Surgery. Journal Of Cardiothoracic And Vascular Anesthesia 2024, 38: 2080-2088. PMID: 38955616, DOI: 10.1053/j.jvca.2024.06.014.Peer-Reviewed Original ResearchConceptsMechanical circulatory supportCardiac surgical patientsPostcardiotomy shockSurgical patientsAssociated with significant morbidityCirculatory supportArea of clinical investigationDecreased systemic perfusionImprove patient survivalTemporary mechanical circulatory supportMCS devicesCardiac surgeryCardiac arrest algorithmCardiac dysfunctionMultiorgan injuryMyocardial impairmentSignificant morbidityPatient survivalSystemic perfusionPoor outcomeClinical managementClinical investigationRestore perfusionClinical experiencePatientsThe impact of emergency guidance to the COVID‐19 pandemic on treatment entry, retention and mortality among patients on methadone in Ukraine
Ivasiy R, Madden L, Meteliuk A, Machavariani E, Ahmad B, Zelenev A, Desai M, Bromberg D, Polonsky M, de Leon S, Farnum S, Islam Z, Altice F. The impact of emergency guidance to the COVID‐19 pandemic on treatment entry, retention and mortality among patients on methadone in Ukraine. Addiction 2024, 119: 1585-1596. PMID: 38807448, DOI: 10.1111/add.16565.Peer-Reviewed Original ResearchOpioid agonist therapyTake-home dosesCOVID-19 guidancePre-COVID cohortAgonist therapyOptimal doseTreatment retentionEmergency guidanceEffective HIV prevention strategiesAdult HIV prevalenceHIV prevention strategiesMinistry of HealthImprove treatment retentionMethadone dosePatient survivalTime-dependent predictorsProspective cohortHIV prevalencePredictors of treatment retentionGovernmental clinicsPrimary outcomeHazard ratioPatient enrollmentPatientsMethadone patientsImpact of Recipient and Donor Body Mass Index on Survival Outcomes After Intestinal Transplantation: A United Network for Organ Sharing Database Analysis
Ameyaw A, Boateng S, Annor E, Njei B. Impact of Recipient and Donor Body Mass Index on Survival Outcomes After Intestinal Transplantation: A United Network for Organ Sharing Database Analysis. Annals Of Transplantation 2024, 29: e943994-1-e943994-13. PMID: 38978263, PMCID: PMC11299477, DOI: 10.12659/aot.943994.Peer-Reviewed Original ResearchConceptsBody mass indexDonor body mass indexIncreased risk of mortalityIntestinal transplantationRisk of mortalityIT recipientsSurvival outcomesMass indexIncreased riskLong-term patient survivalImpact of body mass indexRecipient body mass indexMultivariate Cox regression analysisKaplan-Meier survival curvesBody mass index categoriesLower body mass indexImprove survival outcomesCox regression analysisRetrospective cohort studyAssociation of recipientPost-transplant mortalityImpact of recipientUnderweight patientsPatient survivalObesity classDEPDC5 protects CD8+ T cells from ferroptosis by limiting mTORC1-mediated purine catabolism
Li S, Ouyang X, Sun H, Jin J, Chen Y, Li L, Wang Q, He Y, Wang J, Chen T, Zhong Q, Liang Y, Pierre P, Zou Q, Ye Y, Su B. DEPDC5 protects CD8+ T cells from ferroptosis by limiting mTORC1-mediated purine catabolism. Cell Discovery 2024, 10: 53. PMID: 38763950, PMCID: PMC11102918, DOI: 10.1038/s41421-024-00682-z.Peer-Reviewed Original ResearchCD8+ T cellsPeripheral CD8+ T cellsAnti-tumor immunityT cellsTumor-infiltrating CD8+ T cellsCD8+ T cell homeostasisCD8+ T cell numbersImpaired anti-tumor immunityT cell numbersT-cell protectionT cell homeostasisCancer patient survivalLevels of xanthine oxidasePatient survivalCD8Epilepsy patientsDEPDC5Suppression of ferroptosisMTORC1 signalingFerroptosisMolecular mechanismsImmunityXanthine oxidasePurine catabolismExpressionFinancial toxicity in living donor liver transplantation: A call to action for financial neutrality
Kaplan A, Aby E, Scott S, Sonnenday C, Fox A, Mathur A, Olthoff K, Heimbach J, Ladin K, Emamaullee J, Consortium T, Testa G, Gupta A, Lee S, Fricker Z, Hashimoto K, Kwon D, Emond J, Fox A, Samstein B, Brown R, Rosenblatt R, Kubal A, Gilroy R, King E, Heimbach J, Taner T, Watt K, Chacko K, von Ahrens D, Fortune B, Florman S, Schiano T, Liapakis A, Griesemer A, Orandi B, Caicedo J, Dietch Z, Ganger D, Duarte A, Ravindra K, Kappus M, Melcher M, Bhan I, Tholey D, Kaplan A, Anderson B, Selzner N, Roberts J, Pillai A, DiSabato D, Pomfret E, Jackson W, Maluf D, Sonnenday C, Bloom P, Haakinson D, Chinnakotla S, Aby E, Olthoff K, Abu-Gazala S, Bittermann T, Abt P, Humar A, Ganesh S, Bambha K, Biggins S, Hernandez-Alejandro R, Tomiyama K, Emamaullee J, Kaur N, Han H, Klair T, Yamaguchi S, Cullen J, Baker T, Kim R, Goldaracena N, Sturdevant M, Kwon Y, Garonzik-Wang J, Al-Adra D, Shingina A, Rizzari M, Mulligan D, Rubman S, Batra R, Batisti J. Financial toxicity in living donor liver transplantation: A call to action for financial neutrality. American Journal Of Transplantation 2024, 24: 1742-1754. PMID: 38763318, PMCID: PMC11439575, DOI: 10.1016/j.ajt.2024.05.012.Peer-Reviewed Original ResearchLeave policiesFinancial neutralityIndependent living donor advocateLiving donor advocateFinancial toxicityLiving donor liver transplantationRelief programsCenter useFinancial toolkitDonor liver transplantationDonor advocatePotential living liver donorsImprove equityRate of rejectionLiving liver donorsPatient survivalLiver transplantationFinancial challengesPolicyKeratin 17 modulates the immune topography of pancreatic cancer
Delgado-Coka L, Horowitz M, Torrente-Goncalves M, Roa-Peña L, Leiton C, Hasan M, Babu S, Fassler D, Oentoro J, Bai J, Petricoin E, Matrisian L, Blais E, Marchenko N, Allard F, Jiang W, Larson B, Hendifar A, Chen C, Abousamra S, Samaras D, Kurc T, Saltz J, Escobar-Hoyos L, Shroyer K. Keratin 17 modulates the immune topography of pancreatic cancer. Journal Of Translational Medicine 2024, 22: 443. PMID: 38730319, PMCID: PMC11087249, DOI: 10.1186/s12967-024-05252-1.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaCD8+ T cellsT cellsK17 expressionCell carcinomaPatient survivalMolecular subtypes of pancreatic ductal adenocarcinomaIntratumoral CD8+ T cellsSpatial distribution of T cellsKeratin 17CD8+ T cell abundanceImmune responseSubtype of pancreatic ductal adenocarcinomaCervical squamous cell carcinomaAssociated with decreased numbersCD16+ macrophagesTumor-intrinsic variablesDistribution of T cellsLymph node statusSquamous cell carcinomaBasal cell carcinomaCD163+ macrophagesT cell abundanceImmune cell responsesImmunotherapeutic opportunitiesPaper-based point of care diagnostics for cancer biomarkers
Bhardwaj P, Arora B, Saxena S, Singh S, Palkar P, Goda J, Banerjee R. Paper-based point of care diagnostics for cancer biomarkers. Sensors & Diagnostics 2024, 3: 504-535. DOI: 10.1039/d3sd00340j.Peer-Reviewed Original ResearchPaper-based biosensorsDetection techniquesLow detection limitDetection i.Point-of-care systemLow-cost diagnosisManagement of cancerPoint of care diagnosticsUser-friendlyHome test kitsPatient survivalDetection of cancerAnalyte detectionDiagnosis of cancerDetection limitSignal transmissionSymptomatic detectionPaper chemistryTreatment opportunitiesCancerSignal amplificationAdvanced nanomaterialsEarly detectionCancer detectionClinical samplesImplementing Formal Mitral Heart Team Improves Multidisciplinary Evaluation Rate and Survival of Patients With Severe Primary Mitral Regurgitation
Waldron C, Mori M, Krane M, Reinhardt S, Ahmad Y, Kaple R, Forrest J, Geirsson A. Implementing Formal Mitral Heart Team Improves Multidisciplinary Evaluation Rate and Survival of Patients With Severe Primary Mitral Regurgitation. Journal Of The American Heart Association 2024, 13: e033324. PMID: 38390804, PMCID: PMC11179864, DOI: 10.1161/jaha.123.033324.Peer-Reviewed Original ResearchSevere primary mitral regurgitationPrimary mitral regurgitationHeart failure symptomsMitral regurgitationMultidisciplinary evaluationPatient survivalHeart teamFailure symptomsSociety of Thoracic Surgeons Predicted Risk of MortalityThoracic Surgeons Predicted Risk of MortalityImprove overall patient survivalCorrection of MRAssociated with lower oddsMultidisciplinary heart teamSurvival of patientsAssociated with higher oddsOverall patient survivalProportion of patientsRetrospective cohort studyCardiac surgery servicesHistory of MIOptimal treatment decisionsPropensity-score matchingRisk of mortalityStructural cardiologyUnveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden
Provenzano L, Gwee Y, Conca V, Lonardi S, Bozzarelli S, Tamburini E, Passardi A, Zaniboni A, Tosi F, Aprile G, Nasca V, Boccaccino A, Ambrosini M, Vetere G, Carullo M, Guaglio M, Battaglia L, Zhao J, Chia D, Yong W, Tan P, So J, Kim G, Shabbir A, Ong C, Casella F, Cremolini C, Bencivenga M, Sundar R, Pietrantonio F. Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden. Therapeutic Advances In Medical Oncology 2024, 16: 17588359241289517. PMID: 39502404, PMCID: PMC11536604, DOI: 10.1177/17588359241289517.Peer-Reviewed Original ResearchMetastatic colorectal cancerMetastatic gastric cancerMetastatic gastric cancer patientsPeritoneal metastasisMalignant ascitesAdvanced gastrointestinal cancerSurvival outcomesMedian peritoneal cancer index scoreGastrointestinal cancerPeritoneal cancer index scoreGastric cancerMetastatic colorectal cancer patientsSubgroup of patientsMedian OSProgression-FreeOverall survivalSystemic therapyPrognostic significancePatient survivalAscites groupPoor outcomeRetrospective analysisColorectal cancerRandomized trialsAscites
2023
The Effect of New Acuity Circle Policy on Simultaneous Liver and Kidney Transplantation in the United States
Okumura K, Dhand A, Misawa R, Sogawa H, Veillette G, Nishida S. The Effect of New Acuity Circle Policy on Simultaneous Liver and Kidney Transplantation in the United States. Journal Of Clinical And Experimental Hepatology 2023, 14: 101296. PMID: 38544764, PMCID: PMC10964071, DOI: 10.1016/j.jceh.2023.10.007.Peer-Reviewed Original ResearchSimultaneous liver-kidney transplantationPost-ACS periodKidney graft survivalGraft survivalWaitlist mortalityPatient survivalPost-transplant patient survivalPost-ACSOne-year patient survivalSimultaneous liver-kidney transplant recipientsUnited Network for Organ Sharing databaseEnd-stage liver diseasePost-transplant patientsPost-transplant periodLiver-kidney transplantationPost-transplant outcomesCardiac death organsStudy periodUtilization of donation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply